$1.56T
Total marketcap
$54.03B
Total volume
BTC 49.67%     ETH 16.69%
Dominance

Eli Lilly and Company LLY Stock

584.04 USD {{ price }} -1.184350% {{change_pct}}%
Exchange
NYSE
Market Cap
554.43B USD
LOW - HIGH [24H]
583 - 601.97 USD
VOLUME [24H]
3.18M USD
{{ volume }}
P/E Ratio
105.23
Earnings per share
5.55 USD

Eli Lilly and Company Price Chart

Eli Lilly and Company LLY Financial and Trading Overview

Eli Lilly and Company stock price 584.04 USD
Previous Close 610.5 USD
Open 617.89 USD
Bid 0 USD x 800
Ask 0 USD x 800
Day's Range 602.56 - 629.97 USD
52 Week Range 309.2 - 629.97 USD
Volume 3.97M USD
Avg. Volume 2.96M USD
Market Cap 578.31B USD
Beta (5Y Monthly) 0.331
PE Ratio (TTM) 84.72879
EPS (TTM) 5.55 USD
Forward Dividend & Yield 4.52 (0.73%)
Ex-Dividend Date August 14, 2023
1y Target Est 587.74 USD

LLY Valuation Measures

Enterprise Value 563.95B USD
Trailing P/E 84.72879
Forward P/E 48.349205
PEG Ratio (5 yr expected) 2.3
Price/Sales (ttm) 19.59345
Price/Book (mrq) 49.516376
Enterprise Value/Revenue 19.107
Enterprise Value/EBITDA 57.752

Trading Information

Eli Lilly and Company Stock Price History

Beta (5Y Monthly) 0.331
52-Week Change N/A
S&P500 52-Week Change N/A
52 Week High 629.97 USD
52 Week Low 309.2 USD
50-Day Moving Average 554.17 USD
200-Day Moving Average 430.75 USD

LLY Share Statistics

Avg. Volume (3 month) 2.96M USD
Avg. Daily Volume (10-Days) 3.76M USD
Shares Outstanding 949.29M
Float 897.49M
Short Ratio 2
% Held by Insiders 0.15%
% Held by Institutions 83.98%
Shares Short 5.65M
Short % of Float 0.70%
Short % of Shares Outstanding 0.59%

Dividends & Splits

Trailing Annual Dividend Rate 4.22
Trailing Annual Dividend Yield 0.69%
5 Year Average Dividend Yield 157.00%
Payout Ratio 0.5877
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) June 30, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 22.01%
Operating Margin (ttm) 28.13%
Gross Margin 77.76%
EBITDA Margin 33.08%

Management Effectiveness

Return on Assets (ttm) 10.18%
Return on Equity (ttm) 65.60%

Income Statement

Revenue (ttm) 29.52B USD
Revenue Per Share (ttm) 32.76 USD
Quarterly Revenue Growth (yoy) 28.10%
Gross Profit (ttm) 21.91B USD
EBITDA 9.77B USD
Net Income Avi to Common (ttm) 6.5B USD
Diluted EPS (ttm) 7.19
Quarterly Earnings Growth (yoy) 85.09%

Balance Sheet

Total Cash (mrq) 2.94B USD
Total Cash Per Share (mrq) 3.27 USD
Total Debt (mrq) 18.95B USD
Total Debt/Equity (mrq) 170 USD
Current Ratio (mrq) 1.128
Book Value Per Share (mrq) 12.303

Cash Flow Statement

Operating Cash Flow (ttm) 5.74B USD
Levered Free Cash Flow (ttm) 5.06B USD

Profile of Eli Lilly and Company

Country United States
State IN
City Indianapolis
Address Lilly Corporate Center
ZIP 46285
Phone 317 276 2000
Website https://www.lilly.com
Industry Drug Manufacturers-General
Sector(s) Healthcare
Full Time Employees 39000

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Q&A For Eli Lilly and Company Stock

What is a current LLY stock price?

Eli Lilly and Company LLY stock price today per share is 584.04 USD.

How to purchase Eli Lilly and Company stock?

You can buy LLY shares on the NYSE exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Eli Lilly and Company?

The stock symbol or ticker of Eli Lilly and Company is LLY.

Which industry does the Eli Lilly and Company company belong to?

The Eli Lilly and Company industry is Drug Manufacturers-General.

How many shares does Eli Lilly and Company have in circulation?

The max supply of Eli Lilly and Company shares is 949.31M.

What is Eli Lilly and Company Price to Earnings Ratio (PE Ratio)?

Eli Lilly and Company PE Ratio is 105.23242000 now.

What was Eli Lilly and Company earnings per share over the trailing 12 months (TTM)?

Eli Lilly and Company EPS is 5.55 USD over the trailing 12 months.

Which sector does the Eli Lilly and Company company belong to?

The Eli Lilly and Company sector is Healthcare.

Eli Lilly and Company LLY included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
S&P 500 INDEX SPX 4594.63 USD
+0.59
2.54B USD 4554.71 USD 4599.39 USD 2.54B USD
S&P 500 (Yahoo.com) GSPC 4594.63 USD
+0.59
2.51B USD 4554.71 USD 4599.39 USD 2.51B USD
S&P 100 SP100 2159.78 USD
+0.24
1.23B USD 2144.1 USD 2162.63 USD 1.23B USD
NYSE COMPOSITE (DJ) NYA 16263.75 USD
+1.09
16062.04 USD 16271.7 USD
Nasdaq US Price Setters Index NQPRCE 2331.76 USD
+1.13
2304.5 USD 2331.98 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2272.09 USD
+1.98
2223.51 USD 2272.73 USD
Nasdaq CRD Global Sustainabilit NQCRD 1735.62 USD
0
1715.94 USD 1757.95 USD
The Capital Strength Index seek NQCAPST 2840.47 USD
+0.68
2820 USD 2841.42 USD
NYSE ARCA PHARMACEUTICAL INDEX DRG 885.9 USD
-0.01
882.9 USD 888.48 USD
NASDAQ OMX CRD Global Sustainab QCRD 1595.1 USD
0
Nasdaq US Smart Pharmaceuticals NQSSPH 1332.07 USD
+0.69
1315.97 USD 1332.35 USD
Nasdaq Factor Family US Low Vol NQFFUSLV 1455.72 USD
+0.8
1442.85 USD 1456.27 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1402.5 USD
<0.01
2100.38 AUD 1402.5 USD 2100.38 AUD 1402.5 USD
The Capital Strength Net Total NQCAPSTN 3296.08 USD
+0.69
3272.34 USD 3297.15 USD